GYRE THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
12770 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
Mailing Address
12770 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
Phone
(858) 567-7770
Fiscal Year End
1231
EIN
562020050
Financial Overview
FY2025
$166.13M
Total Assets
$27.00M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 8-K Current report of material events | January 5, 2026 | View on SEC |
| 8-K Current report of material events | November 7, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 7, 2025 | View on SEC |
Annual Reports
10-K
March 13, 2026
- Lead candidate Hydronidone met Phase 3 primary endpoint with 52.85% patient response for liver scarring and received "Breakthrough Therapy" status in China.
- ETUARY® holds a leading ~60% market share in China for IPF, included on the National Reimbursement Drug List (NRDL).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.